Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Interest Receivables: 2024-2025

Historic Change in Interest Receivables for SAB Biotherapeutics (SABS) over the last 2 years, with Sep 2025 value amounting to $559,954.

  • SAB Biotherapeutics' Change in Interest Receivables rose 537.88% to $559,954 in Q3 2025 from the same period last year, while for Sep 2025 it was $462,907, marking a year-over-year change of. This contributed to the annual value of $54,955 for FY2024, which is N/A change from last year.
  • As of Q3 2025, SAB Biotherapeutics' Change in Interest Receivables stood at $559,954, which was up 2,718.32% from -$21,386 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Change in Interest Receivables peaked at $559,954 during Q3 2025, and registered a low of -$127,877 during Q3 2024.
  • Its 2-year average for Change in Interest Receivables is $79,993, with a median of -$21,386 in 2025.
  • Examining YoY changes over the last 5 years, SAB Biotherapeutics' Change in Interest Receivables showed a top increase of 537.88% in 2025 and a maximum decrease of 167.48% in 2025.
  • Over the past 2 years, SAB Biotherapeutics' Change in Interest Receivables (Quarterly) stood at -$42,092 in 2024, then spiked by 537.88% to $559,954 in 2025.
  • Its last three reported values are $559,954 in Q3 2025, -$21,386 for Q2 2025, and -$33,569 during Q1 2025.